TSC22D4 and hypobetalipoproteinemia: TSC22D4 activation, in turn, is sufficient to impair hepatic lipogenesis and to prevent the mobilization of hepatic TG stores into the serum compartment by decreasing hepatic VLDL release, thereby establishing systemic hypo-triglyceridemia and hypobetalipoproteinemia as a hallmark of cancer cachexia and wasting-related metabolic stress conditions.